Purchasers of Namenda, an Alzheimer's drug made by Allergan Plc, requested on Tuesday that a judge in United States District Court in Manhattan confirms their previously agreed upon $750 million settlement with the drugmaker over its violations of antitrust laws.
The purchasers' attorneys announced that it would be the biggest settlement in cases involving a single defendant and multiple purchasers under US generic drug-related federal laws. The plaintiffs claimed that Allergan paid its rival company Mylan NV to postpone the launch of a generic drug called Namenda IR and to sell an extended-release drug Namenda XR instead.
Allergan did not sign any confession to the violation of the law, according to the settlement.
